COCHRANE SERIES, PART 1 – WHAT HAPPENED:
A respected review called a breakthrough Alzheimer’s drug useless. Experts shrugged. Investors, who normally panic on such news, barely noticed. Here’s why that matters — and what it means for families weighing their options.

In a new deal with Alloy Therapeutics, Biogen—the makers of Leqembi—is investing in RNA technology that could point toward what comes next in Alzheimer’s care.

Many diagnosed patients won’t qualify — here are the
7 medical criteria.

New early-onset Alzheimer’s data show that lecanemab can slow functional decline—even while tau continues to spread in the brain. The research helps explain how amyloid-lowering treatments may still preserve daily life, despite the disease’s complexity.

New evidence suggests genetics—not geography—may explain why Leqembi causes fewer ARIA brain side effects in parts of Asia, and what that means for families everywhere.